KEI Comments on NIH Prospective License To Chan Zuckerberg Biohub
On July 17, 2025, KEI submitted comments regarding the prospective Exclusive, Inter-Institutional Agreement-Institution Lead for the development and commercialization of engineered commensals to generate antigen-specific T and B cells (90 FR 29028), which is set to be given to CZ… Continue Reading